MDxHealth Announces Pricing of Offering of Ordinary Shares

Rhea-AI Summary

MDxHealth SA (NASDAQ: MDXH) has announced the pricing of a registered public offering of 20,000,000 ordinary shares at $2.00 per share, aiming to raise $40.0 million in gross proceeds. The offering includes a strategic partner purchasing 1,500,000 shares directly from the company. MDxHealth has granted underwriters an option to purchase up to an additional 2,775,000 shares. The closing is expected on September 27, 2024.

The company plans to use the net proceeds for general corporate and working capital purposes, including funding product development and commercial activities. TD Cowen and William Blair are acting as joint book-running managers, with BTIG, and Lake Street Capital Markets as passive bookrunners for the offering.

Positive

• Raising $40 million in gross proceeds through public offering
• Strategic partner purchasing 1.5 million shares directly from the company
• Underwriters granted option to purchase additional 2.775 million shares
• Funds to be used for product development and commercial activities

Negative

• Potential dilution of existing shareholders' ownership
• Share price set at $2.00, which may be below current market value

Insights

Financial Analyst

This public offering of $40 million is a significant capital raise for MDxHealth, representing over 57% of its current market cap. The pricing at $2.00 per share indicates investor interest, though it's below the current trading price, suggesting some dilution for existing shareholders.

The strategic partner's direct purchase of 1.5 million shares is noteworthy, potentially signaling long-term confidence in the company. The use of proceeds for general corporate purposes and commercial activities suggests MDxHealth is focusing on growth and market expansion in the precision diagnostics space.

While the capital infusion strengthens the balance sheet, investors should monitor how effectively the company deploys these funds to drive revenue growth and path to profitability. The offering's impact on share price and long-term value creation will depend on MDxHealth's execution in the coming quarters.

Medical Research Analyst

As a precision diagnostics company, MDxHealth's substantial capital raise could accelerate its product development and commercial initiatives. The diagnostics market, particularly in oncology, is rapidly evolving with increasing demand for personalized medicine solutions.

This funding could potentially fast-track MDxHealth's pipeline, enhancing its competitive position. However, the diagnostics sector is highly competitive, with larger players like Exact Sciences and Guardant Health dominating certain segments. MDxHealth will need to demonstrate clear differentiation and clinical utility to gain market share.

Investors should closely monitor upcoming clinical data, regulatory milestones and commercial traction for MDxHealth's key products. The company's ability to translate this capital into tangible progress in its diagnostic offerings will be important for long-term success in this dynamic and challenging market.

MDxHealth Announces Pricing of Offering of Ordinary Shares

IRVINE, CA, and HERSTAL, BELGIUM – September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced that it has priced a registered public offering of 20,000,000 ordinary shares of the Company without nominal value (“Ordinary Shares”) in a registered public offering (the “Offering”) at a price to the public of $2.00 per Ordinary Share for total gross proceeds of $40.0 million before deducting commissions and estimated offering expenses. A strategic partner is purchasing 1,500,000 Ordinary Shares in this Offering directly from the Company rather than through the underwriters. In connection with the Offering, mdxhealth has granted the underwriters an option to purchase up to an additional 2,775,000 Ordinary Shares, on the same terms and conditions.

The closing of the Offering is expected to occur on September 27, 2024, subject to the satisfaction of customary closing conditions. The new Ordinary Shares will have the same rights and benefits as, and rank pari passu in all respects, including as to entitlement to dividends and distributions, with, the Company’s existing and outstanding Ordinary Shares and will be entitled to distributions in respect of which the relevant record date or due date falls on or after the date of issue of the new shares.

Mdxhealth intends to use the net proceeds from the Offering for general corporate and working capital purposes, including to fund product development efforts and commercial activities.

TD Cowen and William Blair are acting as joint book-running managers and BTIG, LLC and Lake Street Capital Markets are acting as passive bookrunners for the Offering.

The Ordinary Shares described above are being offered by mdxhealth pursuant to a registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission (“SEC”). A preliminary prospectus supplement relating to the Offering has been filed with the SEC and is available on the SEC’s website at http://www.sec.gov. This press release does not constitute an offer to sell or a solicitation of an offer to buy securities of the Company nor shall there be any offer, solicitation or sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification or publication of an offering prospectus under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities, if at all, has been or will be made in accordance with the registration requirements of the United States Securities Act of 1933 and the European Prospectus Regulation (Regulation (EU) 2017/1129), as relevant.

Copies of the preliminary prospectus supplement, and accompanying base prospectus relating to this offering, may be obtained from TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by email at TD.ECM_Prospectus@tdsecurities.com or by telephone at (855) 495-9846; William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by telephone at (800) 621-0687, or by email at prospectus@williamblair.com; BTIG, LLC, 350 Bush Street, 9th FL, San Francisco, CA 94104, Attention: Syndicate Department (415-248-2200) or by email at prospectusdelivery@btig.com; and Lake Street Capital Markets, LLC, Attention: Syndicate Department, 920 Second Avenue South, Suite 700 Minneapolis, MN 55402, by telephone at (612) 326-1305, or by email at syndicate@lakestreetcm.com.

For more information:

mdxhealth
info@mdxhealth.com

LifeSci Advisors (IR & PR)
US: +1 949 271 9223
ir@mdxhealth.com

IMPORTANT INFORMATION

This press release contains forward-looking statements regarding the expected closing of the Offering and the intended use of proceeds from the Offering. The Offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed. Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially, including those risks disclosed in the section “Risk Factors” included in the preliminary prospectus supplement for the offering and in greater detail in our filings with the SEC. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of mdxhealth in any jurisdiction. No securities of mdxhealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

No public offering will be made and no one has taken any action that would, or is intended to, permit a public offering in any country or jurisdiction, other than the United States, where any such action is required, including in Belgium. Belgian investors, other than qualified investors within the meaning of Regulation (EU) 2017/1129 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market (the “Prospectus Regulation”), will not be eligible to participate in the Offering (whether in Belgium or elsewhere). The transaction to which this press release relates will only be available to, and will be engaged in only with, in member states of the European Economic Area, persons falling within the meaning of Article 2(e) of the Prospectus Regulation, and in the United Kingdom, investment professionals falling within article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), persons falling within article 49 (2), (a) to (d) of the Order and other persons to whom it may lawfully be communicated.

Attachment

• MDXH PR

FAQ

What is the size and price of MDxHealth's (MDXH) public offering?

MDxHealth (MDXH) is offering 20,000,000 ordinary shares at $2.00 per share, aiming to raise $40.0 million in gross proceeds.

When is the expected closing date for MDxHealth's (MDXH) public offering?

The closing of MDxHealth's (MDXH) public offering is expected to occur on September 27, 2024, subject to customary closing conditions.

How does MDxHealth (MDXH) plan to use the proceeds from the offering?

MDxHealth (MDXH) intends to use the net proceeds for general corporate and working capital purposes, including funding product development efforts and commercial activities.

Who are the underwriters for MDxHealth's (MDXH) public offering?

TD Cowen and William Blair are acting as joint book-running managers, while BTIG, and Lake Street Capital Markets are acting as passive bookrunners for the offering.